Stop wasting hours on dense SEC filings. Get AI-powered summaries of any SEC Filings in seconds. Understand key insights and risks, fast.
Currently we only process Form 8-K, 6-K, 3, 4, 144, Schedule 13D and Schedule 13G. We will support more forms in the future.
Filter by Form Type:
Industry:Biotechnologyβ
2026-05-15GDTC3Insider Ownership Filing for CytoMed Therapeutics Ltd
This filing reports the initial ownership of Yvonne Goh, Chief Financial Officer of CytoMed Therapeutics Ltd (GDTC), as of March 18, 2026. Ms. Goh directly owns 25,781 ordinary shares. The filing is made on Form 3, an initial statement of beneficial ownership of securities....
Nano CapBiotechnology
2026-05-15GDTC3Initial Statement of Beneficial Ownership of SecuritiesMEDIUM
This filing details the initial statement of beneficial ownership of securities for Tan Yoong Ying, Chief Corporate Officer of CytoMed Therapeutics Ltd. The report covers the period of March 18, 2026. Tan Yoong Ying holds 25,781 ordinary shares, with no par value, directly. The signature date was May 15, 2026. This fil...
Nano CapBiotechnology
2026-05-15GDTC3Ownership Filing by Choo Chee KongMEDIUM
This filing details the ownership of CytoMed Therapeutics Ltd (GDTC) by Choo Chee Kong. As of March 18, 2026, Mr. Choo directly owns 318,324 ordinary shares. Additionally, he indirectly owns 2,075,310 ordinary shares through his 55% ownership of Glorious Finance Limited and a further 194,112 ordinary shares through EP ...
Nano CapBiotechnology
2026-05-15GDTC3Form 3 Filing: Mark Kei Wei Leong's Initial Statement of Beneficial Ownership for CytoMed Therapeutics
This Form 3 filing reports Mark Kei Wei Leong's initial statement of beneficial ownership in CytoMed Therapeutics Ltd (GDTC). The filing indicates that Leong, who serves as a director of the company, has reported no securities owned as of March 18, 2026. The filing was signed on May 15, 2026, and shows Leong's address ...
Nano CapBiotechnology